menopause%20-and-%20hormone%20therapy
MENOPAUSE & HORMONE THERAPY
Spontaneous/Natural menopause is the final menstrual period confirmed after 12 consecutive months of amenorrhea with no pathological cause.
Induced menopause is the permanent cessation of menstruation after bilateral oophorectomy (ie surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy).
Perimenopause/Menopause transition/Climacteric is the duration when menstrual cycle & endocrine changes occur a few years before and 12 months after the final menstrual period resulting from natural menopause.
Premature menopause is menopause before 40 years of age whether natural or induced while early menopause is spontaneous or induced menopause that occurs before the average age of natural menopause at 51 years or under 45 years of age.

Menopause & Hormone Therapy Drug Information

Drug Information

Indication: Dysmenorrhoea, endometriosis, secondary amenorrhoea, irregular cycles, dysfunctional uterine bleeding, pre-men...

Dosage:  Hormone replacement therapy for women w/ disorders due to natural or surgically induced menopause w/ intact u

Indication: Hormone replacement therapy in postmenopausal women w/ at least 6 mth since last menstruation or surgical meno...

Indication: Premenstruation syndrome, postponement of menstruation, mastodynia, cycle disturbance associated w/ shortening...

Indication: Major depressive disorder.

Indication: Dietary supplement.

Indication: Disorders associated w/ progesterone deficiency eg, infertility due to inadequate luteal phase; for use during...

Indication: Premenstrual syndrome (PMS) including premenstrual tension & depression. Luteal phase support as part of a...

Gynoflor
estriol + lactobacillus acidophilus

Indication: Restoration of lactobacillus flora after anti-infective or chemotherapeutic agents; atrophic vaginitis due to ...

Indication: Complaints resulting from natural or artificial menopause. Prevention of osteoporosis in postmenopausal women ...

1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 5 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.